APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anthrax Vaccines

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Selected research

Market Structure

Global Anthrax Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

1 January 2026191 pages

Choose your research edition.

Industry ResearchAnthrax Vaccines Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Anthrax Vaccines Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Anthrax Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anthrax Vaccines Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Anthrax Vaccines Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Global Anthrax Vaccines key players include Emergent BioSolutions, Merial, Merck, Zoetis, PharmAthene, etc. Global top five players hold a share about 70%.

North America is the largest market, with a share about 60%, followed by Latin America and Europe, having a total share about 20 percent.

Read the full market overview

In terms of product, Live Vaccines is the largest segment, with a share about 95%. And in terms of application, the largest application is Human Use, followed by Animal Use.

This report provides an overview of the global Anthrax Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anthrax Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anthrax Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anthrax Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Anthrax Vaccines Segment by Company

Emergent BioSolutions

Merial

Merck

Zoetis

Bayer Sanidad Animal

Colorado Serum

PharmAthene

Tiankang

Biogénesis-Bago

CAVAC

Rosenbusch

Agrovet

Vecol

CVCRI

IVPM

Prondil

CDV

Indian Immunologicals

Botswana Vaccine Institute

Ceva Santé Animale

Intervac

JOVAC

Anthrax Vaccines Segment by Type

Live Vaccines

Cell free PA Vaccines

Anthrax Vaccines Segment by Application

Human Use

Animal Use

Anthrax Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthrax Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anthrax Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthrax Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anthrax Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anthrax Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anthrax Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anthrax Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anthrax Vaccines Industry Trends Table 2. Anthrax Vaccines Industry Drivers Table 3. Anthrax Vaccines Industry Opportunities and Challenges Table 4. Anthrax Vaccines Industry Restraints Table 5. Global Anthrax Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anthrax Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anthrax Vaccines Sales by Manufacturers (M Doses) & (2021-2026) Table 8. Global Anthrax Vaccines Sales Market Share by Manufacturers Table 9. Global Anthrax Vaccines Average Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 10. Global Anthrax Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anthrax Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anthrax Vaccines Manufacturers, Product Type & Application Table 13. Global Anthrax Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anthrax Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Live Vaccines Table 17. Major Manufacturers of Cell free PA Vaccines Table 18. Global Anthrax Vaccines Sales by Type 2021 VS 2025 VS 2032 (M Doses) Table 19. Global Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 20. Global Anthrax Vaccines Sales by Type (2027-2032) & (M Doses) Table 21. Global Anthrax Vaccines Sales Market Share by Type (2021-2026) Table 22. Global Anthrax Vaccines Sales Market Share by Type (2027-2032) Table 23. Global Anthrax Vaccines Revenue by Type 2021 VS 2025 VS 2032 (M Doses) Table 24. Global Anthrax Vaccines Revenue by Type (2021-2026) & (M Doses) Table 25. Global Anthrax Vaccines Revenue by Type (2027-2032) & (M Doses) Table 26. Global Anthrax Vaccines Revenue Market Share by Type (2021-2026) Table 27. Global Anthrax Vaccines Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Human Use Table 29. Major Manufacturers of Animal Use Table 30. Global Anthrax Vaccines Sales by Application 2021 VS 2025 VS 2032 (M Doses) Table 31. Global Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 32. Global Anthrax Vaccines Sales by Application (2027-2032) & (M Doses) Table 33. Global Anthrax Vaccines Sales Market Share by Application (2021-2026) Table 34. Global Anthrax Vaccines Sales Market Share by Application (2027-2032) Table 35. Global Anthrax Vaccines Revenue by Application 2021 VS 2025 VS 2032 (M Doses) Table 36. Global Anthrax Vaccines Revenue by Application (2021-2026) & (M Doses) Table 37. Global Anthrax Vaccines Revenue by Application (2027-2032) & (M Doses) Table 38. Global Anthrax Vaccines Revenue Market Share by Application (2021-2026) Table 39. Global Anthrax Vaccines Revenue Market Share by Application (2027-2032) Table 40. Global Anthrax Vaccines Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 41. Global Anthrax Vaccines Sales by Region (2021-2026) & (M Doses) Table 42. Global Anthrax Vaccines Sales Market Share by Region (2021-2026) Table 43. Global Anthrax Vaccines Sales Forecasted by Region (2027-2032) & (M Doses) Table 44. Global Anthrax Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Anthrax Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 46. North America Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 47. North America Anthrax Vaccines Sales by Country (2027-2032) & (M Doses) Table 48. Europe Anthrax Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 49. Europe Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 50. Europe Anthrax Vaccines Sales by Country (2027-2032) & (M Doses) Table 51. Asia Pacific Anthrax Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 52. Asia Pacific Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 53. Asia Pacific Anthrax Vaccines Sales by Country (2027-2032) & (M Doses) Table 54. South America, Middle East and Africa Anthrax Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 55. South America, Middle East and Africa Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 56. South America, Middle East and Africa Anthrax Vaccines Sales by Country (2027-2032) & (M Doses) Table 57. Global Anthrax Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Anthrax Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Anthrax Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Anthrax Vaccines Revenue Market Share by Region (2021-2026) Table 61. Global Anthrax Vaccines Revenue Market Share by Region (2027-2032) Table 62. Emergent BioSolutions Company Information Table 63. Emergent BioSolutions Business Overview Table 64. Emergent BioSolutions Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Emergent BioSolutions Anthrax Vaccines Product Portfolio Table 66. Emergent BioSolutions Recent Development Table 67. Merial Company Information Table 68. Merial Business Overview Table 69. Merial Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Merial Anthrax Vaccines Product Portfolio Table 71. Merial Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Merck Anthrax Vaccines Product Portfolio Table 76. Merck Recent Development Table 77. Zoetis Company Information Table 78. Zoetis Business Overview Table 79. Zoetis Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Zoetis Anthrax Vaccines Product Portfolio Table 81. Zoetis Recent Development Table 82. Bayer Sanidad Animal Company Information Table 83. Bayer Sanidad Animal Business Overview Table 84. Bayer Sanidad Animal Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Bayer Sanidad Animal Anthrax Vaccines Product Portfolio Table 86. Bayer Sanidad Animal Recent Development Table 87. Colorado Serum Company Information Table 88. Colorado Serum Business Overview Table 89. Colorado Serum Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Colorado Serum Anthrax Vaccines Product Portfolio Table 91. Colorado Serum Recent Development Table 92. PharmAthene Company Information Table 93. PharmAthene Business Overview Table 94. PharmAthene Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. PharmAthene Anthrax Vaccines Product Portfolio Table 96. PharmAthene Recent Development Table 97. Tiankang Company Information Table 98. Tiankang Business Overview Table 99. Tiankang Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Tiankang Anthrax Vaccines Product Portfolio Table 101. Tiankang Recent Development Table 102. Biogénesis-Bago Company Information Table 103. Biogénesis-Bago Business Overview Table 104. Biogénesis-Bago Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Biogénesis-Bago Anthrax Vaccines Product Portfolio Table 106. Biogénesis-Bago Recent Development Table 107. CAVAC Company Information Table 108. CAVAC Business Overview Table 109. CAVAC Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. CAVAC Anthrax Vaccines Product Portfolio Table 111. CAVAC Recent Development Table 112. Rosenbusch Company Information Table 113. Rosenbusch Business Overview Table 114. Rosenbusch Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Rosenbusch Anthrax Vaccines Product Portfolio Table 116. Rosenbusch Recent Development Table 117. Agrovet Company Information Table 118. Agrovet Business Overview Table 119. Agrovet Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Agrovet Anthrax Vaccines Product Portfolio Table 121. Agrovet Recent Development Table 122. Vecol Company Information Table 123. Vecol Business Overview Table 124. Vecol Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Vecol Anthrax Vaccines Product Portfolio Table 126. Vecol Recent Development Table 127. CVCRI Company Information Table 128. CVCRI Business Overview Table 129. CVCRI Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. CVCRI Anthrax Vaccines Product Portfolio Table 131. CVCRI Recent Development Table 132. IVPM Company Information Table 133. IVPM Business Overview Table 134. IVPM Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. IVPM Anthrax Vaccines Product Portfolio Table 136. IVPM Recent Development Table 137. Prondil Company Information Table 138. Prondil Business Overview Table 139. Prondil Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Prondil Anthrax Vaccines Product Portfolio Table 141. Prondil Recent Development Table 142. CDV Company Information Table 143. CDV Business Overview Table 144. CDV Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. CDV Anthrax Vaccines Product Portfolio Table 146. CDV Recent Development Table 147. Indian Immunologicals Company Information Table 148. Indian Immunologicals Business Overview Table 149. Indian Immunologicals Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Indian Immunologicals Anthrax Vaccines Product Portfolio Table 151. Indian Immunologicals Recent Development Table 152. Botswana Vaccine Institute Company Information Table 153. Botswana Vaccine Institute Business Overview Table 154. Botswana Vaccine Institute Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Botswana Vaccine Institute Anthrax Vaccines Product Portfolio Table 156. Botswana Vaccine Institute Recent Development Table 157. Ceva Santé Animale Company Information Table 158. Ceva Santé Animale Business Overview Table 159. Ceva Santé Animale Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. Ceva Santé Animale Anthrax Vaccines Product Portfolio Table 161. Ceva Santé Animale Recent Development Table 162. Intervac Company Information Table 163. Intervac Business Overview Table 164. Intervac Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 165. Intervac Anthrax Vaccines Product Portfolio Table 166. Intervac Recent Development Table 167. JOVAC Company Information Table 168. JOVAC Business Overview Table 169. JOVAC Anthrax Vaccines Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 170. JOVAC Anthrax Vaccines Product Portfolio Table 171. JOVAC Recent Development Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Anthrax Vaccines Distributors List Table 175. Anthrax Vaccines Customers List Table 176. Research Programs/Design for This Report Table 177. Authors List of This Report Table 178. Secondary Sources Table 179. Primary Sources List of Figures Figure 1. Anthrax Vaccines Product Image Figure 2. Global Anthrax Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anthrax Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Anthrax Vaccines Sales (2021-2032) & (M Doses) Figure 5. Global Anthrax Vaccines Average Price (USD/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Anthrax Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Live Vaccines Image Figure 9. Cell free PA Vaccines Image Figure 10. Global Anthrax Vaccines Sales by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 11. Global Anthrax Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Anthrax Vaccines Sales Market Share by Type (2021-2032) Figure 13. Global Anthrax Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 14. Global Anthrax Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Anthrax Vaccines Revenue Market Share by Type (2021-2032) Figure 16. Human Use Image Figure 17. Animal Use Image Figure 18. Global Anthrax Vaccines Sales by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 19. Global Anthrax Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Anthrax Vaccines Sales Market Share by Application (2021-2032) Figure 21. Global Anthrax Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 22. Global Anthrax Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Anthrax Vaccines Revenue Market Share by Application (2021-2032) Figure 24. North America Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 25. North America Anthrax Vaccines Sales Market Share by Country (2021-2032) Figure 26. U.S. Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 27. Canada Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 28. Mexico Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 29. Europe Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 30. Europe Anthrax Vaccines Sales Market Share by Country (2021-2032) Figure 31. Germany Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 32. France Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 33. U.K. Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 34. Italy Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 35. Netherlands Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 36. Asia Pacific Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 37. Asia Pacific Anthrax Vaccines Sales Market Share by Country (2021-2032) Figure 38. China Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 39. Japan Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 40. South Korea Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 41. Southeast Asia Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 42. India Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 43. Australia Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 44. South America, Middle East and Africa Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 45. South America, Middle East and Africa Anthrax Vaccines Sales Market Share by Country (2021-2032) Figure 46. Brazil Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 47. South Africa Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 48. Saudi Arabia Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 49. Turkey Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 50. Argentina Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 51. UAE Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 52. Egypt Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 53. Chile Anthrax Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 54. Global Anthrax Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Anthrax Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Figure 57. North America Anthrax Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Figure 59. Europe Anthrax Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Anthrax Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Anthrax Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Anthrax Vaccines Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Anthrax Vaccines Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Live Vaccines
  • Cell free PA Vaccines
Applications
  • Human Use
  • Animal Use
Companies covered
  • Emergent BioSolutions
  • Merial
  • Merck
  • Zoetis
  • Bayer Sanidad Animal
  • Colorado Serum
  • PharmAthene
  • Tiankang
  • Biogénesis-Bago
  • CAVAC
  • Rosenbusch
  • Agrovet
  • Vecol
  • CVCRI
  • IVPM
  • Prondil
  • CDV
  • Indian Immunologicals
  • Botswana Vaccine Institute
  • Ceva Santé Animale
  • Intervac
  • JOVAC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anthrax Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anthrax Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anthrax Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anthrax Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anthrax Vaccines Market Dynamics
  1. 2.1 Anthrax Vaccines Industry Trends
  2. 2.2 Anthrax Vaccines Industry Drivers
  3. 2.3 Anthrax Vaccines Industry Opportunities and Challenges
  4. 2.4 Anthrax Vaccines Industry Restraints
3 Anthrax Vaccines Market by Manufacturers
  1. 3.1 Global Anthrax Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anthrax Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anthrax Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anthrax Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anthrax Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anthrax Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Anthrax Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anthrax Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anthrax Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anthrax Vaccines Tier 1, Tier 2, and Tier 3
4 Anthrax Vaccines Market by Type
  1. 4.1 Anthrax Vaccines Type Introduction
  2. 4.1.1 Live Vaccines
  3. 4.1.2 Cell free PA Vaccines
  4. 4.2 Global Anthrax Vaccines Sales by Type
  5. 4.2.1 Global Anthrax Vaccines Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anthrax Vaccines Sales by Type (2021-2032)
  7. 4.2.3 Global Anthrax Vaccines Sales Market Share by Type (2021-2032)
  8. 4.3 Global Anthrax Vaccines Revenue by Type
  9. 4.3.1 Global Anthrax Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anthrax Vaccines Revenue by Type (2021-2032)
  11. 4.3.3 Global Anthrax Vaccines Revenue Market Share by Type (2021-2032)
5 Anthrax Vaccines Market by Application
  1. 5.1 Anthrax Vaccines Application Introduction
  2. 5.1.1 Human Use
  3. 5.1.2 Animal Use
  4. 5.2 Global Anthrax Vaccines Sales by Application
  5. 5.2.1 Global Anthrax Vaccines Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Anthrax Vaccines Sales by Application (2021-2032)
  7. 5.2.3 Global Anthrax Vaccines Sales Market Share by Application (2021-2032)
  8. 5.3 Global Anthrax Vaccines Revenue by Application
  9. 5.3.1 Global Anthrax Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Anthrax Vaccines Revenue by Application (2021-2032)
  11. 5.3.3 Global Anthrax Vaccines Revenue Market Share by Application (2021-2032)
6 Global Anthrax Vaccines Sales by Region
  1. 6.1 Global Anthrax Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anthrax Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Anthrax Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Anthrax Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anthrax Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anthrax Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anthrax Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anthrax Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anthrax Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anthrax Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anthrax Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anthrax Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anthrax Vaccines Revenue by Region
  1. 7.1 Global Anthrax Vaccines Revenue by Region
  2. 7.1.1 Global Anthrax Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anthrax Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Anthrax Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Anthrax Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anthrax Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Anthrax Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anthrax Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Anthrax Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anthrax Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anthrax Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anthrax Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anthrax Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Emergent BioSolutions
  2. 8.1.1 Emergent BioSolutions Company Information
  3. 8.1.2 Emergent BioSolutions Business Overview
  4. 8.1.3 Emergent BioSolutions Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Emergent BioSolutions Anthrax Vaccines Product Portfolio
  6. 8.1.5 Emergent BioSolutions Recent Developments
  7. 8.2 Merial
  8. 8.2.1 Merial Company Information
  9. 8.2.2 Merial Business Overview
  10. 8.2.3 Merial Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merial Anthrax Vaccines Product Portfolio
  12. 8.2.5 Merial Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Anthrax Vaccines Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Zoetis
  20. 8.4.1 Zoetis Company Information
  21. 8.4.2 Zoetis Business Overview
  22. 8.4.3 Zoetis Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zoetis Anthrax Vaccines Product Portfolio
  24. 8.4.5 Zoetis Recent Developments
  25. 8.5 Bayer Sanidad Animal
  26. 8.5.1 Bayer Sanidad Animal Company Information
  27. 8.5.2 Bayer Sanidad Animal Business Overview
  28. 8.5.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Sanidad Animal Anthrax Vaccines Product Portfolio
  30. 8.5.5 Bayer Sanidad Animal Recent Developments
  31. 8.6 Colorado Serum
  32. 8.6.1 Colorado Serum Company Information
  33. 8.6.2 Colorado Serum Business Overview
  34. 8.6.3 Colorado Serum Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Colorado Serum Anthrax Vaccines Product Portfolio
  36. 8.6.5 Colorado Serum Recent Developments
  37. 8.7 PharmAthene
  38. 8.7.1 PharmAthene Company Information
  39. 8.7.2 PharmAthene Business Overview
  40. 8.7.3 PharmAthene Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 PharmAthene Anthrax Vaccines Product Portfolio
  42. 8.7.5 PharmAthene Recent Developments
  43. 8.8 Tiankang
  44. 8.8.1 Tiankang Company Information
  45. 8.8.2 Tiankang Business Overview
  46. 8.8.3 Tiankang Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Tiankang Anthrax Vaccines Product Portfolio
  48. 8.8.5 Tiankang Recent Developments
  49. 8.9 Biogénesis-Bago
  50. 8.9.1 Biogénesis-Bago Company Information
  51. 8.9.2 Biogénesis-Bago Business Overview
  52. 8.9.3 Biogénesis-Bago Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Biogénesis-Bago Anthrax Vaccines Product Portfolio
  54. 8.9.5 Biogénesis-Bago Recent Developments
  55. 8.10 CAVAC
  56. 8.10.1 CAVAC Company Information
  57. 8.10.2 CAVAC Business Overview
  58. 8.10.3 CAVAC Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CAVAC Anthrax Vaccines Product Portfolio
  60. 8.10.5 CAVAC Recent Developments
  61. 8.11 Rosenbusch
  62. 8.11.1 Rosenbusch Company Information
  63. 8.11.2 Rosenbusch Business Overview
  64. 8.11.3 Rosenbusch Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Rosenbusch Anthrax Vaccines Product Portfolio
  66. 8.11.5 Rosenbusch Recent Developments
  67. 8.12 Agrovet
  68. 8.12.1 Agrovet Company Information
  69. 8.12.2 Agrovet Business Overview
  70. 8.12.3 Agrovet Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Agrovet Anthrax Vaccines Product Portfolio
  72. 8.12.5 Agrovet Recent Developments
  73. 8.13 Vecol
  74. 8.13.1 Vecol Company Information
  75. 8.13.2 Vecol Business Overview
  76. 8.13.3 Vecol Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Vecol Anthrax Vaccines Product Portfolio
  78. 8.13.5 Vecol Recent Developments
  79. 8.14 CVCRI
  80. 8.14.1 CVCRI Company Information
  81. 8.14.2 CVCRI Business Overview
  82. 8.14.3 CVCRI Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CVCRI Anthrax Vaccines Product Portfolio
  84. 8.14.5 CVCRI Recent Developments
  85. 8.15 IVPM
  86. 8.15.1 IVPM Company Information
  87. 8.15.2 IVPM Business Overview
  88. 8.15.3 IVPM Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 IVPM Anthrax Vaccines Product Portfolio
  90. 8.15.5 IVPM Recent Developments
  91. 8.16 Prondil
  92. 8.16.1 Prondil Company Information
  93. 8.16.2 Prondil Business Overview
  94. 8.16.3 Prondil Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Prondil Anthrax Vaccines Product Portfolio
  96. 8.16.5 Prondil Recent Developments
  97. 8.17 CDV
  98. 8.17.1 CDV Company Information
  99. 8.17.2 CDV Business Overview
  100. 8.17.3 CDV Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CDV Anthrax Vaccines Product Portfolio
  102. 8.17.5 CDV Recent Developments
  103. 8.18 Indian Immunologicals
  104. 8.18.1 Indian Immunologicals Company Information
  105. 8.18.2 Indian Immunologicals Business Overview
  106. 8.18.3 Indian Immunologicals Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Indian Immunologicals Anthrax Vaccines Product Portfolio
  108. 8.18.5 Indian Immunologicals Recent Developments
  109. 8.19 Botswana Vaccine Institute
  110. 8.19.1 Botswana Vaccine Institute Company Information
  111. 8.19.2 Botswana Vaccine Institute Business Overview
  112. 8.19.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Botswana Vaccine Institute Anthrax Vaccines Product Portfolio
  114. 8.19.5 Botswana Vaccine Institute Recent Developments
  115. 8.20 Ceva Santé Animale
  116. 8.20.1 Ceva Santé Animale Company Information
  117. 8.20.2 Ceva Santé Animale Business Overview
  118. 8.20.3 Ceva Santé Animale Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Ceva Santé Animale Anthrax Vaccines Product Portfolio
  120. 8.20.5 Ceva Santé Animale Recent Developments
  121. 8.21 Intervac
  122. 8.21.1 Intervac Company Information
  123. 8.21.2 Intervac Business Overview
  124. 8.21.3 Intervac Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Intervac Anthrax Vaccines Product Portfolio
  126. 8.21.5 Intervac Recent Developments
  127. 8.22 JOVAC
  128. 8.22.1 JOVAC Company Information
  129. 8.22.2 JOVAC Business Overview
  130. 8.22.3 JOVAC Anthrax Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 JOVAC Anthrax Vaccines Product Portfolio
  132. 8.22.5 JOVAC Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anthrax Vaccines Value Chain Analysis
  2. 9.1.1 Anthrax Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anthrax Vaccines Production Mode & Process
  6. 9.2 Anthrax Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anthrax Vaccines Distributors
  9. 9.2.3 Anthrax Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst